ees erythromycin 200mg/5ml (as ethyl succinate) granules for oral liquid bottle
amdipharm mercury australia pty ltd - erythromycin ethyl succinate -
erythromycin ethyl succinate 125mg/5ml oral suspension
pinewood healthcare - erythromycin ethyl succinate - oral suspension - 25mg/1ml
erythromycin ethyl succinate 250mg/5ml oral suspension
pinewood healthcare - erythromycin ethyl succinate - oral suspension - 50mg/1ml
erythromycin ethyl succinate 125mg/5ml oral suspension sugar free
pinewood healthcare - erythromycin ethyl succinate - oral suspension - 25mg/1ml
erythromycin ethyl succinate 250mg/5ml oral suspension sugar free
pinewood healthcare - erythromycin ethyl succinate - oral suspension - 50mg/1ml
e-mycin 400 erythromycin 400mg/5ml powder for oral liquid
alphapharm pty ltd - erythromycin ethyl succinate, quantity: 468 mg (equivalent: erythromycin, qty 400 mg) - oral liquid, powder for - excipient ingredients: sorbitol; propylene glycol alginate; sodium citrate dihydrate; erythrosine; aspartame; sodium benzoate; colloidal anhydrous silica; flavour - streptococcus pyogenes (group a beta-haemolytic streptococcus). upper and lower respiratory tract, skin and skin structure infections of mild to moderate severity. when oral medication is given, patient must comply with the prescribed regimen. therapeutic dose should be administered for at least 10 days. alpha haemolytic streptococci (viridans group). no controlled clinical efficacy trials have been conducted, however oral erythromycin has been suggested by the american heart association and the american dental association for use in bacterial endocarditis prophylaxis prior to dental/surgical procedures of the upper respiratory tract in penicillin-hypersensitive patients with a history of rheumatic, congenital or other acquired valvular heart disease. erythromycin is unsuitable prior to genitourinary or gastrointestinal tract surgery. staphylococcus aureus. acute infections of skin and skin structure of mild to moderate severity. bacterial resistance may emerge during treatment, hence cultures and sensitivity
e-mycin 200 erythromycin 200mg/5ml powder for oral liquid
alphapharm pty ltd - erythromycin ethyl succinate, quantity: 234 mg (equivalent: erythromycin, qty 200 mg) - oral liquid, powder for - excipient ingredients: sorbitol; propylene glycol alginate; sodium citrate dihydrate; erythrosine; aspartame; sodium benzoate; colloidal anhydrous silica; flavour - streptococcus pyogenes (group a beta-haemolytic streptococcus). upper and lower respiratory tract, skin and skin structure infections of mild to moderate severity. when oral medication is given, patient must comply with the prescribed regimen. therapeutic dose should be administered for at least 10 days. alpha haemolytic streptococci (viridans group). no controlled clinical efficacy trials have been conducted, however oral erythromycin has been suggested by the american heart association and the american dental association for use in bacterial endocarditis prophylaxis prior to dental/surgical procedures of the upper respiratory tract in penicillin-hypersensitive patients with a history of rheumatic, congenital or other acquired valvular heart disease. erythromycin is unsuitable prior to genitourinary or gastrointestinal tract surgery. staphylococcus aureus. acute infections of skin and skin structure of mild to moderate severity. bacterial resistance may emerge during treatment, hence cultures and sensitivity
erythromycin ethyl succinate 500mg/5ml oral suspension sugar free
pinewood healthcare - erythromycin ethyl succinate - oral suspension - 100mg/1ml
erythromycin ethyl succinate 500mg/5ml oral suspension
pinewood healthcare - erythromycin ethyl succinate - oral suspension - 100mg/1ml
erythromycin ethyl succinate 500mg tablets
sigma pharmaceuticals plc - erythromycin ethyl succinate - oral tablet - 500mg